Norwegian clinical-stage immunoncology company, Lytix Biopharma, has entered into a clinical collaboration with US-based Iovance Biotherapeutics.
Norwegian clinical-stage immunoncology company, Lytix Biopharma, has entered into a clinical collaboration with US-based Iovance Biotherapeutics, it was unveiled in a Nov. 10, 2019 press release.
The companies will collaborate to evaluate Lytix’s first-in-class oncolytic peptide, LTX-315, in combination with Iovance’s autologous ready to infuse T-cell therapy. Under the terms of the non-exclusive agreement, both companies will retain ownership of their own assets.
“We are very excited about the collaboration with Iovance, and the combination of our technologies can be a potential new approach to T cell therapy for cancers,” said Øystein Rekdal, CEO of Lytix Biopharma. “This agreement affirms that we remain committed to the further development of LTX-315 as a single agent and in combination with other therapies.”
Source: Lytix Biopharma
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 2nd 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.